NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Alumis Inc. (ALMS) Stock Analysis

Alumis Inc. (ALMS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ALMS

$6.81

+$0.11 (+1.64%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ALMS with… →

ALMS Key Statistics

As of Oct 21, 2026
Trading
Open
$6.75
Previous Close
$6.70
Day's Range
6.66–6.95
52-Week Range
4.37–31.35
Volume
1.23M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.37
Valuation
Market Cap
$881.45M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
119.15
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.86
Financials (FY)
Revenue (FY)
$24.05M
Net Income (FY)
−$243.33M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
129.44M
1-Year Return
+46.77%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
2.54M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ALMS closed at $6.81, +46.77% over 1 year.

Alumis Inc. (ALMS) has a market capitalization of $881.45M.

In fiscal 2025, ALMS reported revenue of $24.05M.

ALMS Stock Return by Calendar Year

Alumis Inc. (ALMS) return since Jun 2024: what $10,000 became

1 year
$10,000 $14,677
+46.77%
Since Jun 2024
$10,000 $5,120
−48.80%

If you had invested $10,000 in Alumis Inc. (ALMS) at the close on June 28, 2024, the earliest close on record here, it would have been worth $5,120 at the close on October 21, 2026: −48.80% in total, −25.12% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−30.23%
2025+24.17%
2024 (partial year)−40.90%

As of October 21, 2026.

ALMS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$24.05M−$243.33M−1,011.7%
2024$0.00−$294.23M—
2023$0.00−$154.99M—
2022$0.00−$111.93M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$24.05M—−$453.80M−$243.33M−1,011.7%
2024$0.00—−$300.75M−$294.23M—
2023$0.00—−$158.17M−$154.99M—
2022$0.00—−$113.85M−$111.93M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ALMS Valuation vs Biotechnology Median

Median of 608 stocks
MetricALMSBiotechnology medianvs median
P/S ratio119.1513.309.0x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Alumis Inc. (ALMS) is capitalised at $881.45M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 237.

The 52-week range on file runs from $4.37 to $31.35. The most recent close on file for ALMS is $6.81, dated October 21, 2026. That is +$0.11 (+1.64%) against the previous close. The latest close sits 55.84% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $24.05M. The same year closed with a net loss of $243.33M. Earnings per share on a trailing basis come to −3.86.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $24.05M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 119.15 times revenue. On price-to-sales that is 9 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The reported beta is −0.37. Daily returns over the trailing 2 years annualize to a volatility of 122.92%. Over the trailing twelve months the total return is +46.77%. The stored price history starts on June 28, 2024, and the total return since then is −48.80%.

Growth & Income

No dividend is on file for ALMS.

2026 is still running; the total return is −30.23% year to date. The record holds one complete calendar year, 2025, which returned +24.17%.

Peer Comparison

Alumis Inc. (ALMS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Alumis Inc. ALMS $881.45M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Alumis Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Alumis Inc.

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.

Visit website →